Captor Therapeutics SA
WSE:CTX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| PL |
C
|
Captor Therapeutics SA
WSE:CTX
|
457.9m PLN |
Loading...
|
|
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
223.7B USD |
Loading...
|
|
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR |
Loading...
|
|
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD |
Loading...
|
|
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
107.1B ZAR |
Loading...
|
|
| US |
|
Schlumberger NV
NYSE:SLB
|
76.9B USD |
Loading...
|
|
| US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
61.5B USD |
Loading...
|
|
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
47.7B USD |
Loading...
|
|
| CH |
G
|
Galderma Group AG
SIX:GALD
|
36.8B CHF |
Loading...
|
|
| ID |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
564.8T IDR |
Loading...
|
|
| US |
|
Symbotic Inc
NASDAQ:SYM
|
33.2B USD |
Loading...
|
Market Distribution
| Min | -535 500% |
| 30th Percentile | 18.1% |
| Median | 30.2% |
| 70th Percentile | 55.9% |
| Max | 807.1% |
Other Profitability Ratios
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Captor Therapeutics SA is 48%, which is below its 3-year median of 63.4%.
Over the last 3 years, Captor Therapeutics SA’s Gross Margin has decreased from 72.1% to 48%. During this period, it reached a low of 48% on Jul 30, 2025 and a high of 83.6% on Jun 30, 2023.
